Form 4: National Healthcare Corp CEO Stephen Flatt Reports Stock Option Grant and Restricted Share Award
SEC Form 4 Filing
CEO Stephen Flatt reports the acquisition of stock options and restricted shares in National Healthcare Corp.
Summary
- On March 5, 2024, Stephen Flatt, CEO of National Healthcare Corp, reported the acquisition of 2,783 shares of common stock and 15,000 stock options.
- The 2,783 shares are restricted and will vest in three equal installments on January 1, 2025, 2026, and 2027.
- The 15,000 stock options, granted under the 2020 Omnibus Equity Incentive Plan, have an exercise price of $94.10.
- These options will vest ratably over three years, starting March 5, 2025, and expiring on March 5, 2029.
- Following these transactions, Flatt directly owns 59,535 shares of common stock and 34,734 stock options.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The grant of stock options and restricted shares is a standard practice and aligns management with shareholder interests. The vesting schedule promotes long-term value creation.
Positives
- The grant of restricted shares and stock options aligns the CEO's interests with those of the shareholders.
- The vesting schedules encourage long-term performance and retention of the CEO.
Industry Context
Equity grants to executives are a common practice in the healthcare industry to incentivize performance and align management's interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the healthcare sector, similar to companies like Brookdale Senior Living and HCA Healthcare.
- The vesting schedules for both the restricted shares and stock options are typical, aligning with industry norms for long-term incentive plans.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize the CEO to improve company performance.
- Employees may be motivated by the alignment of executive compensation with company success.
Key Dates
| Date | Description |
|---|---|
| 02/18/2023 | Date of previously granted stock options with an exercise price of $63.96 |
| 03/05/2024 | Date of transaction: Grant of restricted shares and stock options |
| 03/07/2024 | Date of Form 4 filing |
| 03/08/2024 | Date of previously granted stock options with an exercise price of $53.94 |
| 03/05/2025 | First vesting date for one-third of the newly granted stock options |
| 01/01/2025 | First vesting date for one-third of the restricted shares |
| 03/05/2026 | Second vesting date for one-third of the newly granted stock options |
| 01/01/2026 | Second vesting date for one-third of the restricted shares |
| 03/05/2027 | Final vesting date for one-third of the newly granted stock options |
| 01/01/2027 | Final vesting date for one-third of the restricted shares |
| 02/18/2027 | Expiration date of previously granted stock options with an exercise price of $63.96 |
| 03/05/2029 | Expiration date of newly granted stock options |
| 03/08/2028 | Expiration date of previously granted stock options with an exercise price of $53.94 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.